Jianqu veterinary grade API is released as a crystalline solid with assay 98.0–102.0% on dried basis and moisture below 0.5% for injection grade and 1.0% for oral grade. The oral grade complies with impurity and residual solvent expectations under VICH GL18; the injection grade is endotoxin-controlled per Ph.Eur. 2.6.14. A direct-compaction route for Jianqu veterinary tablets becomes technically feasible only when the API particle-size distribution and the lubricant blend are tightly controlled. The released lot is first characterized for loss on drying per Ph.Eur. 2.2.32; values above 1.0% w/w require pre-drying in a vacuum tray dryer at 40°C and 200 mbar for 2 h because residual moisture initiates cap-shaped fractures at main compression pressures above 14 kN. A representative tablet formula for a 200 mg strength contains 40–60% w/w Jianqu API, microcrystalline cellulose (Ph.Eur. type 102), crospovidone 2–5% w/w, and sodium starch glycolate 2–4% w/w; the dry blend is passed through a 630 μm screen into a 100 L bin blender and mixed at 12 rpm for 10 min. If the API D90 is above 150 μm, content uniformity at 200 mg tablet weight routinely fails the Ph.Eur. 2.9.40 acceptance value ≤15; the corrective step is deagglomeration through a conical screen mill fitted with a 0.5 mm round screen at 1,500 rpm, bringing D90 to 45–60 μm. A 16-station rotary tablet press with 8 mm round concave tooling runs at 40–60 rpm; precompression is set to 4–6 kN and main compression to 10–18 kN, producing hardness of 60–90 N and friability per Ph.Eur. 2.9.7 below 1.0%. Higher hardness is not used because it extends disintegration beyond 15 min at 37°C in 0.1 M hydrochloric acid. Magnesium stearate is added at 0.5% w/w through a 250 μm screen; total lubrication time above 5 min lowers tablet tensile strength by up to 30% due to hydrophobic surface coverage of MCC, which is the limiting quality attribute rather than ejected tablet hardness. Aqueous film coating with hypromellose 6 cP at 10% w/w solids uses inlet air temperature 60–65°C, spray rate 8–12 g/min per gun, and coating weight gain 3.0%; pan bed temperature below 45°C causes tablet edge erosion and visual defects.

At batch scales above 300 kg, bin blender segregation is measured by stratified sampling after discharge; the acceptance criterion for blend uniformity is an RSD below 5% and the mean assay within 95–105% of target. Compaction force data from the rotary press are logged every 15 min; a drift in main compression force of more than 2 kN across the batch is investigated because it shifts tablet hardness and dissolution. The tablet press is fitted with a dry granulation unit only when the API fraction exceeds 60% w/w; at that loading, direct compression becomes sensitive to punch sticking, and the formulation is changed to a roller-compacted granule with 2% w/w crospovidone intra-granular and 2% w/w extra-granular. Ejection force is recorded continuously; values above 1,000 N indicate insufficient lubrication and are corrected by adding magnesium stearate up to 0.75% w/w, not by increasing punch pressure. Final blend analytical release includes identification by HPLC with diode-array detection, assay, water content, and uniformity of dosage units; the limit for total degradation products is 1.0% area normalized and any unknown single impurity above 0.2% is identified before batch disposition.

How Does Terminal Sterilization Affect Jianqu Injection Clarity and Assay Recovery?

Jianqu parenteral solutions are compounded by dissolving the injection-grade API in Water for Injection, adjusting pH with dilute hydrochloric acid to 3.5–4.5, and adding sodium chloride to 0.9% w/v when isotonicity is required; the free base form shows limited solubility above pH 5.0, and cold storage at 2–8°C can produce visible precipitation within 24 h if the pH drifts upward. The bulk solution is clarified through a 0.45 μm polyethersulfone pre-filter and sterilized through a 0.22 μm PES final filter. Filter capacity is usually above 200 L/m² at 20–25°C; cooling below 10°C raises solution viscosity enough to reduce throughput by 15–20%, so filtration is conducted at controlled room temperature. Terminal autoclaving at 121°C for 15 min is preferred when the container is a 20 mL amber borosilicate glass vial with a bromobutyl stopper; however, residual oxygen in the headspace causes assay loss above 2% per cycle unless nitrogen sparging reduces dissolved oxygen below 1 ppm before capping. The fill volume is set at 20.2 mL to satisfy extractable volume testing under Ph.Eur. 2.9.17. For lyophilized presentations, the matrix contains 2.5–5.0% w/v mannitol and 0.5–1.0% w/v glycine; the cycle freezes to -40°C, primary dries at -20°C and 100 mTorr for 10 h, and secondary dries at 40°C for 4 h until residual moisture is below 0.5% by Karl Fischer titration. Collapse temperature data published for this specific configuration are limited; therefore the primary drying pressure is held at 100 mTorr and the product temperature monitored with thermocouples in edge vials to avoid cake collapse.

The injectable stability program follows VICH GL3 with storage at 40°C/75% RH and 25°C/60% RH; each pull point includes assay, related substances per VICH GL18, pH, and particulate matter per Ph.Eur. 2.9.19. For sub-visible particles, the limit is 600 particles/vial for particles ≥10 µm and 60 particles/vial for particles ≥25 µm; batches exceeding these levels require additional filtration or dilution rather than longer autoclave cycles. Endotoxin content is controlled to 0.25 EU/mL per Ph.Eur. 2.6.14 and sterility is demonstrated by membrane filtration per Ph.Eur. 2.6.1. The buffering system is 10 mM citrate; higher buffer strength increases local injection-site irritation in target species, which is monitored in the target animal safety study rather than by analytical release testing.

In capsule filling suites where Jianqu API is dispensed as a pre-blend into hard gelatin or HPMC capsules, the primary process variable is the compressive flow of the powder at the dosator or tamping pin. A 100 mg strength is filled at 300–400 mg into size 1 capsules, using lactose monohydrate 60–70% w/w, pregelatinized starch 10–15% w/w, and sodium lauryl sulfate 0.5–1.0% w/w; the blend is screened through 0.8 mm and mixed in a 200 L V-blender at 10 rpm for 15 min. Flow behavior is accepted only when the Carr index is below 25% and the Hausner ratio is below 1.25; if Jianqu API is milled to a D90 of 100–120 μm, flow is generally acceptable without glidant, whereas a D90 below 50 μm requires colloidal silicon dioxide at 0.5% w/w and a reduced filling speed. Capsule weight variation is monitored under Ph.Eur. 2.9.5 using 20 individual capsules; the acceptance criterion is ±10% of the mean fill weight for the registered strength. Dissolution testing follows Ph.Eur. 2.9.3 with 900 mL of 0.1 M hydrochloric acid at 37°C and 50 rpm paddle speed; the release specification is Q ≥ 80% at 45 min, because slower dissolution in a veterinary patient can reduce absorbed dose and require dose adjustment. Empty capsules are stored at 35–45% RH for gelatin or 40–50% RH for HPMC shells before filling; lower humidity causes gelatin embrittlement and higher humidity softens HPMC shells, which leads to splitting or seam collapse on the filling machine.

Medicated Premix Lines Require Carrier Selection and Carryover Validation Before Jianqu API Is Diluted

On a medicated premix line, Jianqu veterinary API at 1–10 g/kg active concentration is blended in a horizontal ribbon mixer of 500 kg capacity with blade clearance 2–5 mm; the carrier is usually ground corn cob, limestone, or rice hull, with 0.5–1.0% w/w mineral oil added to bind fine dust. Sampling for homogeneity follows ISO 6497:2002, with 10–12 grab samples collected after denning and assayed by a validated HPLC method; a batch passes when the coefficient of variation is below 5%, and batches above 8% are re-mixed in 5 min increments. Carrier selection is not neutral: limestone has higher bulk density and lower oil absorption than corn cob, which changes the segregation profile when the premix is transferred through screw augers; corn cob with bulk density 0.35–0.45 g/mL gives better API adhesion but produces more dust in the blending room. The carryover limit for a following non-target species batch is set at 1% of the therapeutic concentration; a validated flush sequence of 10 kg carrier per mixer is run after every Jianqu-containing batch, and the first 5 kg of the flushed material is discarded. These controls fall under medicated feed GMP expectations in 21 CFR Part 225 and EU Regulation (EU) 2019/4, with in-process checks under 21 CFR 211.110 where the premix is treated as a dosage form intermediate.

Final feed dilution to 1–100 ppm target dose is performed in a vertical screw mixer or auger at 5–10 rpm; the mixing time is validated by tracer studies using iron oxide or a salt tracer, not by assumption. Dust suppression is critical because the fine Jianqu API fraction below 20 μm can represent 15–25% of total particles and remains airborne beyond 30 s in a 0.5 m/s downflow booth. Extraction systems should capture particulate above 10 µm at 99% efficiency; operators handle the premix in full suits with approved respiratory protection during open transfers. Analytical recovery from carrier matrices is matrix-matched because corn cob adsorbs the API less than limestone; extraction uses 80% methanol with 0.1% formic acid, and recovery is considered acceptable only between 90–110% across the premix concentration range.

When Wet Granulation Is Selected for Jianqu Granules, the Critical Parameter Is Endpoint Torque Rather Than Binder Concentration

In high-shear wet granulation of Jianqu veterinary granules, the main constraint is the API’s tendency to partially dissolve and recrystallize on the particle surface during the wet massing phase. The granulation liquid is a 5% w/v povidone K30 solution in deionized water, added at 3–5% w/w relative to dry powder mass through an atomizing nozzle at 2 bar; impeller speed is set to 150–200 rpm and chopper speed to 1,500–2,000 rpm. The endpoint is defined by an impeller torque increase of 20–30% above dry-mix baseline rather than by fixed granulation time, because the torque curve plateaus when the mean granule size reaches 300–500 μm. Torque below 15 Nm on a 65 L granulator typically produces weak granules that break to fines during fluid-bed drying; torque above 40 Nm produces dense granules with slower dissolution because the API migrates into the outer film. After wet massing, the granulate is transferred to a fluid-bed dryer; inlet air is 55–60°C, product temperature is kept below 45°C, and the endpoint is set at loss on drying 1.0–2.0% per Ph.Eur. 2.2.32. Dried granules are screened through a 1.0 mm oscillating sieve; overs above 20% are passed through a low-speed blade mill, but mill speeds above 3,000 rpm generate fines below 75 μm that must be removed or re-granulated to avoid segregation.

If the Jianqu API is moisture-sensitive, dry granulation by roller compaction is preferred because residual water induces hydrolysis at the granule surface when acidic granulation agents are used. Roller compaction is performed with a 120 mm roll diameter, roll pressure 20–40 kN/cm, gap 1.5–2.0 mm, and roll speed 5–10 rpm; the compacted ribbon is milled through a 0.8 mm screen to produce granules with a D50 of 250–350 μm. Compacted granules have a bulk density of 0.65–0.75 g/mL, which reduces capsule or sachet fill volume for the same dose compared with wet-granulated material. The roller-compacted granulate is checked for friability and compressibility; friability above 1.0% indicates weak compacts and requires raising roll pressure or reducing roll gap, while excessive capping during tableting indicates overcompaction and requires lowering roll pressure before the final compression stage.

pH Buffering and Preservative Compatibility in Jianqu Oral Solutions

Jianqu oral solutions are formulated at 10–50 mg/mL active concentration in aqueous vehicles containing propylene glycol 10–20% v/v and a 10–25 mM buffer system to hold pH between 4.0 and 5.5. The lower pH boundary is set by palatability in target species and the upper boundary by precipitation when the solution is stored at 2–8°C; a pH excursion above 5.5 can produce a visible haze that does not resuspend without warming to 25°C. Preservative efficacy is tested by Ph.Eur. 5.1.3; sodium benzoate at 0.1–0.2% w/v is used only below pH 5.0 because benzoic acid loses activity above its pKa of 4.2, while potassium sorbate at 0.1% w/v is substituted at pH 5.0–5.5. The solution is filled into 100 mL amber poly(ethylene terephthalate) bottles and the extractable volume is checked per Ph.Eur. 2.9.17. Headspace oxygen is kept below 5% v/v by nitrogen purging before capping, because photodegradation and oxidation are the main degradation routes in this aqueous system rather than hydrolysis alone.

Stability is monitored under VICH GL3 at 25°C/60% RH and 40°C/75% RH for 6 months; appearance, assay, pH, related substances, and microbial limits are tested at each pull. If the product is dosed through drinking water lines, the medication is diluted to 1:200 or 1:500 in water; line mixing equipment must achieve a coefficient of variation below 10% at the nipple drinker. Precipitation at the drinker line occurs when water hardness is above 300 ppm CaCO₃ because calcium ions interact with the buffer system; a compatibility trial under local water sources is therefore required before field use. The photostability test is performed according to Ph.Eur. 2.2.29, and the amber bottle must meet the requirement of transmitted light below 10% at wavelengths below 450 nm if photodegradation is observed.

For powder and granule sachets containing Jianqu API for in-water or in-feed dosing, a different set of packaging controls is required than for tablets. The finished powder is dosed into stick packs or sachets of 1–10 g using a form-fill-seal machine with an auger filler; fill weight tolerances follow Ph.Eur. 2.9.40 with an acceptance value ≤15 for single-dose preparations. The powder blend contains Jianqu API at 1–20% w/w, with dextrose or lactose monohydrate as the diluent and a desiccant such as anhydrous calcium sulfate at 0.5–1.0% w/w. If the fill target is 5 g and the particle-size distribution has a high fraction below 50 μm, electrostatic attraction to the film forming shoe causes fill weight variation above 3%; the corrective step is to add 0.5% w/w colloidal silicon dioxide and maintain relative humidity at 40–50% in the filling suite. Heat-seal integrity is tested by vacuum decay per ASTM F2338-09 or equivalent; seal failure at 200 mbar indicates a breached package that exposes the powder to moisture. The sachet material is a multi-layer laminate of polyester/aluminum/linear low-density polyethylene, with aluminum thickness ≥9 μm, because a moisture vapor transmission rate above 0.02 g/m²/day at 38°C/90% RH causes caking and assay loss after 3 months. Reconstitution studies use 100 mL water at 25°C and 35°C, measuring dispersion time and whether the powder passes through a 500 μm sieve without residue; residues above 1% of the filled mass fail the dispersion specification and require reformulation or a smaller fill weight.